Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:09PM EDT. Market open.
| Previous close | 903.48 |
| Open | 900.00 |
| Bid | 939.43 x 100 |
| Ask | 943.23 x 100 |
| Day's range | 891.60 - 943.77 |
| 52-week range | 684.81 - 998.33 |
| Volume | |
| Avg. volume | 463,095 |
| Market cap | 103.758B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 27.08 |
| EPS (TTM) | 34.77 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,051.33 |
Investor's Business DailyRegeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
ZacksRegeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
ZacksRegeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
© 2024 Yahoo. All rights reserved.